For research use only. Not for therapeutic Use.
Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
| Catalog Number | I047424 |
| Purity | ≥95% |
| Reference | [1] Deeks ED. Drugs. 2019;79(13):1467-1475. |
